P2.03-054 EGFR Mutation with Acquired C-MET Positive Reveals Potential Immunotherapeutic Vulnerabilities

MLA

Shan Su, et al. “P2.03-054 EGFR Mutation with Acquired C-MET Positive Reveals Potential Immunotherapeutic Vulnerabilities.” Journal of Thoracic Oncology, vol. 12, Nov. 2017, p. S2395. EBSCOhost, https://doi.org/10.1016/j.jtho.2017.11.009.

APA

Shan Su, Zhi-Hong Chen, Zhong-Yi Dong, X. Zhang, J.-J. Yang, Jian Su, Y-L. Wu, & Zhi Xie. (2017). P2.03-054 EGFR Mutation with Acquired C-MET Positive Reveals Potential Immunotherapeutic Vulnerabilities. Journal of Thoracic Oncology, 12, S2395. https://doi.org/10.1016/j.jtho.2017.11.009

Chicago

Shan Su, Zhi-Hong Chen, Zhong-Yi Dong, X. Zhang, J.-J. Yang, Jian Su, Y-L. Wu, and Zhi Xie. 2017. “P2.03-054 EGFR Mutation with Acquired C-MET Positive Reveals Potential Immunotherapeutic Vulnerabilities.” Journal of Thoracic Oncology 12 (November): S2395. doi:10.1016/j.jtho.2017.11.009.